The Effect of AST-120, Absorbent of Uremic Toxins on The Severity of Cardiac Failure in Patient with Chronic Heart Failure - The Effect of AST-120, Absorbent of Uremic Toxins on The Severity of Cardiac Failure in Patient with Chronic Heart Failure (AST-HF study)

AST-HF study office0 个研究点目标入组 50 人开始时间: 2018年9月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients with an allergic history of AST-120 2) Patients already treated with AST-120 3) Patients with stage 5 CKD 4) Patients suspected or diagnosed with Nephrotic syndrome 5) Patients using mechanical circulatory support devices 6) Patients waiting for heart transplant 7) Patients waiting for cardiac surgery 8) Patients with New York Heart Association (NYHA) Functional Classification, class III or IV at baseline 9) Patients with any past histories of acute coronary syndrome or coronary intervention or cardiac surgery developed within 6 months 10) Patients who start cardiac resynchronization therapy within 6 months 11) Patients who start beta blocker treatment within 6 months 12) Patients who start or change some drugs for heart failure or diabetes within 3 months 13) Patients expected to live less than 3 years 14) Patients with possible alcohol or drug abuse 15) Patients who are pregnant or possibly pregnant 16) Patients with breast feeding 17) Patients with disorder of gastrointestinal transit 18) Patients with gastrointestinal ulcer or esophageal varix 19) Patients who are prone to constipation 20) Patients who have been enrolled in other clinical studies at the same time with this study (excluding observational studies such as registry studies) 21) Patients who are judged by the investigator or subinvestigators to be not suitable for participation in the study

发起方

AST-HF study office